ENDRA Life Sciences Book Value 2011-2026 | NDRA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value ENDRA Life Sciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
2.26 M	2.56 M	5.66 M	7.2 M	10.8 M	7.17 M	4.76 M	6.25 M	5.28 M	-894 K	250 K	605 K	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
10.8 M	-894 K	4.32 M

Quarterly Book Value ENDRA Life Sciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
171 K	1.47 M	1.75 M	2.56 M	-	8.99 M	3.7 M	5.66 M	5.2 M	6.93 M	4.5 M	7.2 M	10.2 M	13.3 M	9.07 M	10.8 M	13.2 M	15 M	17.9 M	7.17 M	3.33 M	7.17 M	7.17 M	4.76 M	4.76 M	4.76 M	4.76 M	6.25 M	6.25 M	6.25 M	6.25 M	5.28 M	5.28 M	5.28 M	5.28 M	-894 K	-894 K	-894 K	-894 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
17.9 M	-894 K	5.89 M

Book Value of other stocks in the Diagnostics research industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	77.2 M	-	-6.23 %	$ 30.6 M	Germany
Burning Rock Biotech Limited BNR	1.85 B	$ 15.85	-2.49 %	$ 171 M	China
Agilent Technologies A	5.39 B	$ 115.06	-0.29 %	$ 35 B	USA
Aspira Women's Health AWH	-6.93 M	-	-6.19 %	$ 10.5 M	USA
Biocept BIOC	8.86 M	-	-13.05 %	$ 7.29 M	USA
BioNano Genomics BNGO	44.4 M	$ 1.13	-2.59 %	$ 6.15 M	USA
Chembio Diagnostics CEMI	17.8 M	-	0.22 %	$ 16.8 M	USA
Check-Cap Ltd. CHEK	-1.45 M	-	-	$ 9.42 M	Israel
DermTech DMTK	57.2 M	-	-11.32 %	$ 2.94 M	USA
CareDx, Inc CDNA	303 M	$ 16.05	-3.83 %	$ 855 M	USA
Oxford Immunotec Global PLC OXFD	16.7 M	-	-	$ 562 M	Britain
Akumin AKU	141 M	-	-17.87 %	$ 25.9 M	Canada
Enzo Biochem ENZ	56.1 M	-	-8.98 %	$ 14.8 K	USA
Co-Diagnostics CODX	20.6 M	$ 4.4	101.83 %	$ 5.85 M	USA
Exact Sciences Corporation EXAS	2.4 B	-	-	$ 19.8 B	USA
Accelerate Diagnostics AXDX	-22.3 M	-	-61.36 %	$ 2.46 M	USA
Castle Biosciences CSTL	456 M	$ 23.13	-1.28 %	$ 642 M	USA
Global Cord Blood Corporation CO	4.88 B	-	-	$ 399 M	China
Fluidigm Corporation FLDM	132 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	16.4 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	548 M	-	0.12 %	$ 80.1 M	China
Interpace Biosciences IDXG	22.4 M	$ 2.3	-	$ 10.2 M	USA
Charles River Laboratories International CRL	3.21 B	$ 175.65	0.06 %	$ 8.71 B	USA
PRA Health Sciences, Inc. PRAH	1.32 B	-	-	$ 10.7 B	USA
Danaher Corporation DHR	83.5 B	$ 189.61	-1.7 %	$ 135 B	USA
Heska Corporation HSKA	422 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	5.39 M	-	-20.0 %	$ 1.06 M	USA
Medpace Holdings MEDP	459 M	$ 493.53	-1.59 %	$ 14.2 B	USA
Illumina ILMN	6.3 B	$ 120.93	-2.22 %	$ 19.2 B	USA
Fulgent Genetics FLGT	1.13 B	$ 14.43	-3.93 %	$ 436 M	USA
Myriad Genetics MYGN	368 M	$ 4.35	-2.03 %	$ 403 M	USA
NeoGenomics NEO	837 M	$ 7.69	-3.17 %	$ 985 M	USA
Guardant Health GH	-99.3 M	$ 78.6	-9.83 %	$ 9.85 B	USA
QIAGEN N.V. QGEN	6.15 B	-	-	$ 10.6 B	Niderland
Anixa Biosciences ANIX	14 M	$ 2.69	-1.82 %	$ 87.3 K	USA
Biomerica BMRA	4.1 M	$ 2.13	-0.9 %	$ 4.89 M	USA
Invitae Corporation NVTA	102 M	-	-	$ 21.2 M	USA
Koninklijke Philips N.V. PHG	11 B	$ 28.31	0.62 %	$ 20 B	Niderland
ICON Public Limited Company ICLR	9.52 B	$ 106.81	0.1 %	$ 8.81 B	Irlanda
Laboratory Corporation of America Holdings LH	8.64 B	$ 260.93	-4.51 %	$ 21.7 B	USA
Natera NTRA	706 M	$ 193.03	-4.91 %	$ 19 B	USA
Celcuity CELC	101 M	$ 117.14	-6.02 %	$ 5.48 B	USA
Lantheus Holdings LNTH	1.09 B	$ 80.59	-1.03 %	$ 5.44 B	USA
Motus GI Holdings MOTS	2.69 M	-	-34.28 %	$ 263 K	Israel
Quest Diagnostics Incorporated DGX	16.2 B	$ 191.51	-3.19 %	$ 21.3 B	USA
Neogen Corporation NEOG	2.07 B	$ 9.42	-6.13 %	$ 2.04 B	USA
Organovo Holdings ONVO	10.5 M	-	-2.3 %	$ 19.4 M	USA
OpGen OPGN	7.38 M	-	-16.95 %	$ 1.54 M	USA
National Research Corporation NRC	14 M	$ 16.48	-3.34 %	$ 369 M	USA